Study reveals that COVID-19 significantly increases the risk of chronic fatigue syndrome, with specific populations, such as older adults, Asians, and non-hospitalized patients, at higher risk.
Fusion Pharma marks in-house radiopharma manufacturing success, details PhII/III trial study
Fusion Pharmaceuticals said it has manufactured the first clinical dose of its radiopharmaceutical asset in-house and has agreed with the FDA on the design of